Sarepta and Roche halt DMD gene therapy’s use after second death

Sarepta and Roche have halted commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys in non-ambulatory patients following a second fatal acute liver failure (ALF) case. Roche has stopped commercial use and paused clinical trial enrollment, while Sarepta is temporarily suspending shipments and convening experts to enhance the immunosuppression regimen. This decision follows a safety profile reassessment, prompting a 31.34% drop in Sarepta's pre-market trading and a 1% decline in Roche's shares, raising investor concerns about the therapy's future despite analysts viewing a complete removal from the market as unlikely.

Analysis

Sarepta Therapeutics and its global partner Roche have discontinued the commercial and clinical use of their Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, for non-ambulatory patients due to severe safety concerns. This decision follows a safety profile reassessment prompted by a second patient death from acute liver failure (ALF) linked to the therapy; two fatal ALF cases have now been associated with Elevidys. Consequently, Roche has immediately halted commercial use and paused enrollment in clinical trials for this patient group, while Sarepta is temporarily suspending shipments for non-ambulatory patients and urgently convening an expert panel to develop an enhanced immunosuppression regimen. The market reaction has been significant, with Sarepta's shares plummeting 31.34% in pre-market trading on the Nasdaq, and Roche's shares declining 1% at market open, reflecting the extremely negative sentiment (-0.85 overall, -0.9 for SRPT) and high market impact score (0.8) associated with this development. Despite Elevidys being the only approved gene therapy in the US for DMD in individuals aged four and older (both ambulatory and non-ambulatory), William Blair analyst Sami Corwin noted that while a complete market removal is viewed as unlikely, Elevidys's label will probably be updated to include the risk of ALF, and another patient death will amplify investor concerns. The first fatal ALF case, reported in March 2025, had already led to the suspension of multiple Elevidys clinical trials, which remain on hold.

Key Decisions for Investors

• Investors in Sarepta Therapeutics (SRPT) should anticipate continued significant stock price volatility and closely monitor communications regarding the proposed enhanced immunosuppression regimen and subsequent FDA feedback, as these will be crucial for Elevidys's future in the non-ambulatory patient segment.
• Evaluate the potential for a materially restricted market for Elevidys, considering the possibility that enhanced safety measures may not fully restore confidence or that the label update could significantly limit its application, despite current analyst expectations that a full withdrawal is improbable.
• For Roche investors, while the direct impact is less pronounced, assess the implications for the ex-US commercialization strategy of Elevidys and the potential read-through to the risk assessment of its broader gene therapy portfolio.